JachietM, FlageulB, DerouxA, et al.; French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: Data from a French nationwide study. Arthritis Rheumatol. 2015; 67(2):527–534; doi: 10.1002/art.38912
3.
NaranjoCA, BustoU, SellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239–245; doi: 10.1038/clpt.1981.154
4.
de BritoM, HuebnerG, MurrellDF, et al.Normocomplementaemic urticarial vasculitis: Effective treatment with omalizumab. Clin Transl Allergy. 2018; 8:37; doi: 10.1186/s13601-018-0215-6
5.
HoppensteadtDA, FareedJ. Pharmacological profile of sulodexide. Int Angiol. 2014; 33(3):229–235.
6.
DammanJ, MooyaartAL, SeelenMAJ, et al.Dermal C4d Deposition and neutrophil alignment along the dermal-epidermal junction as a diagnostic adjunct for hypocomplementemic urticarial vasculitis (Anti-C1q Vasculitis) and underlying systemic disease. Am J Dermatopathol. 2020; 42(6):399–406; doi: 10.1097/DAD.0000000000001501
